Neurocrine Biosciences, Inc. NBIX
164.85 USD +19.50 (+13.42%)
At closeNov 3, 2026, 4:42 PM EST
164.85 0.00 0.00%
After hours · Nov 3, 4:42 PM ET
157.91 Day range 169.53
122.14 52-week range 186.12
- YTD
- +16.23%
- 1 year
- +16.12%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 206.79 +25.4% upside
Now 164.85
- Target (low)
- 150.00
- Target (mean)
- 206.79
- Target (high)
- 253.00
Ratings (0m) 29 25 buy · 4 hold · 0 sell
- Strong buy4
- Buy21
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 29
- 1 month ago 29
- 2 months ago 29
- 3 months ago 28
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.75 | 2.07 – 3.33 | 1.88 | +46.0% | 1.09B | +34.7% | 17 |
| Next quarter | 2.79 | 2.55 – 3.07 | 1.88 | +48.2% | 1.07B | +31.6% | 11 |
| Current year | 10.64 | 10.39 – 11.11 | 6.39 | +66.5% | 3.90B | +36.5% | 5 |
| Next year | 11.97 | 8.37 – 16.06 | 10.64 | +12.5% | 4.58B | +17.2% | 15 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Nov 3, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 3, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 3, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Oct 16, 2026 | Needham | Reiterated | Buy | Buy |
| Oct 12, 2026 | BMO Capital | Maintained | Market Perform | Market Perform |
| Sep 29, 2026 | UBS | Maintained | Buy | Buy |
| Sep 11, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Sep 8, 2026 | RBC Capital | Reiterated | Outperform | Outperform |
| Sep 3, 2026 | Citigroup | Maintained | Buy | Buy |
| Aug 13, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Aug 3, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 3, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 3, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jul 31, 2026 | Citigroup | Maintained | Buy | Buy |
| Jul 31, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 31, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jul 31, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jul 31, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Jul 31, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Jul 31, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 31, 2026 | Stifel | Maintained | Buy | Buy |
| Jul 31, 2026 | Needham | Maintained | Buy | Buy |
| Jul 21, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 17, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 13, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jul 13, 2026 | BMO Capital | Maintained | Market Perform | Market Perform |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jun 30, 2026 | UBS | Maintained | Buy | Buy |
| May 29, 2026 | RBC Capital | Maintained | Outperform | Outperform |
